Wall Street brokerages forecast that vTv Therapeutics Inc (NASDAQ:VTVT) will announce earnings per share (EPS) of ($0.11) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for vTv Therapeutics’ earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.05). vTv Therapeutics posted earnings of ($0.29) per share during the same quarter last year, which would indicate a positive year over year growth rate of 62.1%. The business is expected to report its next earnings results on Friday, August 2nd.
According to Zacks, analysts expect that vTv Therapeutics will report full-year earnings of ($0.59) per share for the current financial year. For the next financial year, analysts anticipate that the firm will report earnings of ($0.40) per share, with EPS estimates ranging from ($0.60) to ($0.19). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($0.26) EPS for the quarter. The business had revenue of $0.92 million for the quarter.
In related news, major shareholder Ronald O. Perelman bought 1,358,698 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $1.84 per share, for a total transaction of $2,500,004.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.70% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley boosted its position in vTv Therapeutics by 147,061.5% during the 1st quarter. Morgan Stanley now owns 19,131 shares of the biotechnology company’s stock worth $33,000 after buying an additional 19,118 shares during the period. Sabby Management LLC acquired a new stake in vTv Therapeutics during the 1st quarter worth approximately $382,000. Wedbush Securities Inc. acquired a new stake in vTv Therapeutics during the 1st quarter worth approximately $30,000. D. E. Shaw & Co. Inc. acquired a new stake in vTv Therapeutics during the 4th quarter worth approximately $186,000. Finally, Barclays PLC boosted its position in vTv Therapeutics by 366.7% during the 4th quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock worth $74,000 after buying an additional 22,000 shares during the period. Institutional investors own 3.94% of the company’s stock.
VTVT stock traded down $0.14 during trading hours on Friday, reaching $1.40. The stock had a trading volume of 1,116,457 shares, compared to its average volume of 1,146,659. The stock has a market cap of $84.03 million, a P/E ratio of -2.03 and a beta of -3.70. vTv Therapeutics has a fifty-two week low of $0.68 and a fifty-two week high of $6.09.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
See Also: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.